Soleno Therapeutics in our Pivotal Point Check: Stifel Sees "Blockbuster Opportunity" in the FDA Approval of Vykat XR for the Treatment of Prader-Willi Syndrome!
Reading Time: 2 minutes
Soleno Therapeutics has achieved a milestone in the rare disease market. The treatment with Diazoxide-Choline aims to address extreme hunger in patients with Prader-Willi Syndrome. Vykat XR is expected to reach peak sales of approximately $2 billion. Soleno Therapeutics rose by 37% on March 27, 2025, as investors celebrated the news that the company received FDA approval for Vykat XR. The treatment with Diazoxide-Choline aims to address extreme hunger in patients with Prader-Willi Syndrome. The syndrome is a rare genetic disorder...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
